China’s Supreme Court Upholds Novo Nordisk’s Semaglutide Patent
Table of Contents
A landmark ruling by China’s Supreme People’s Court on December 31, 2025, has affirmed the validity of Novo Nordisk’s patent for the semaglutide compound, a critical development for the pharmaceutical giant and a signal of strengthening intellectual property protections in the region.
The decision upholds a previous ruling by the Beijing Intellectual Property Court, solidifying Novo Nordisk’s rights to the compound used in its blockbuster drugs. “This outcome is very positive for semaglutide and demonstrates firm government support for protecting medical innovation,” stated a company representative. “This decision also strengthens confidence for foreign companies’ sustainable development in China and will motivate further development and introduction of innovative medicines for the benefit of patients.”
Semaglutide, a glucagon-like peptide-1 (GLP-1) analogue, is the active ingredient in several widely-used medications. These include Wegovy, prescribed for weight management and obesity, and Ozempic and Rybelsus, used in the treatment of type 2 diabetes. Since its launch, the compound has accumulated approximately 38 million patient-years of clinical use, demonstrating its significant impact on global healthcare.
Implications for Global Sales and Innovation
While the patent ruling is a significant win for Novo Nordisk, the company has previously indicated that the eventual expiration of the compound patent in certain international markets is anticipated to have a limited impact on overall sales. Analysts estimate a low-single-digit percentage decrease in global sales growth in 2026 as a result of these expirations. However, the recent Chinese court decision does not alter this previously communicated forecast.
The ruling is particularly noteworthy as it signals a commitment from the Chinese government to protect intellectual property rights, a key concern for international pharmaceutical companies operating within the country. This increased confidence could encourage further investment in research and development, leading to the introduction of more innovative medicines to benefit patients in China and beyond.
Novo Nordisk’s Global Footprint
Founded in 1923 and headquartered in Denmark, Novo Nordisk has grown into a leading global healthcare company dedicated to combating serious chronic diseases, with a historical focus on diabetes. The company’s mission centers on scientific breakthroughs, expanding access to vital medications, and ultimately finding cures for debilitating illnesses.
Novo Nordisk currently employs approximately 78,500 people across 80 countries, marketing its products in around 170 countries worldwide.
For more information about Novo Nordisk, visit novonordisk.com.
You can also find them on Facebook, Instagram, X, LinkedIn, and YouTube.
